David Powers, MD
Nephrology · Covington, LANPI 1548265812
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,413 of the $34,648 with a category attached, or 64.7%. AstraZeneca accounts for 85.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $23,800 and has fallen 97.6% since, to $580 in 2024. Among nephrology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $130.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- Amgen$1K
- Otsuka America Pharmaceutical, Inc.$844
- Bayer$828
- OPKO Pharmaceuticals, LLC$362
- Nxstage Medical, Inc.$300
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$22,41365%
- Travel & lodging$5,61016%
- Food & beverage$6,52819%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 68 | $29,609 |
| Amgen(2 entities) | 59 | $1,352 |
| Otsuka America Pharmaceutical, Inc. | 44 | $844 |
| Bayer | 30 | $828 |
| OPKO Pharmaceuticals, LLC | 16 | $362 |
| Nxstage Medical, Inc. | 2 | $300 |
| Calliditas Therapeutics US Inc. | 6 | $198 |
| Vifor Pharma, Inc. | 10 | $173 |
| Aspira Women's Health Inc | 1 | $162 |
| Akebia Therapeutics Inc | 9 | $153 |
| Daiichi Sankyo Inc. | 6 | $113 |
| Aurinia Pharma U.S., Inc. | 2 | $102 |
| Tesaro, Inc. | 1 | $101 |
| AbbVie | 1 | $85 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $79 |
| Eisai Inc. | 1 | $72 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Novartis | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,648 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $246,948 |
| AuryxiaFerric Citrate | 87 | $171,099 |
| VelphoroSucroferric Oxyhydroxide | 52 | $116,288 |
| FarxigaDapagliflozin Propanediol | 45 | $29,992 |
| JardianceEmpagliflozin | 24 | $26,638 |
| Lanthanum Carbonate | 23 | $24,832 |
| Sevelamer Carbonate | 114 | $17,384 |
| KerendiaFinerenone | 13 | $10,384 |
| Calcium Acetate | 35 | $4,277 |
| Clonidine | 14 | $1,804 |
| Nifedipine ErNifedipine | 29 | $1,128 |
| Allopurinol | 173 | $1,010 |
| Calcitriol | 66 | $861 |
| Midodrine Hcl | 11 | $766 |
| Potassium Chloride | 50 | $729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $844 | $246,94813 claims |
| Akebia Therapeutics IncAuryxia | $153 | $171,09987 claims |
| Fresenius USA Marketing, Inc.Velphoro | $34 | $116,28852 claims |
| AstraZenecaFarxiga | $29,609 | $29,99245 claims |
| BayerKerendia | $828 | $10,38413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Covington
- Jon MaresCovington$103K
- Peter vanCovington$8K
- Imran ShujaCovington$5K
- Sreedhara AllaShreveport$722K
- Anthony BlalockLafayette$350K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Raja ZabanehShreveport$57K
- Michael TouchyNew Orleans$56K
- Kenneth AbreoShreveport$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.